Attention Deficit Hyperactivity Disorder (ADHD) Market Size, Share, Industry, Forecast and outlook (2023-2030)

Attention Deficit Hyperactivity Disorder (ADHD) Market is segmented By Drug Type (Stimulant, Non-stimulant), By Age Group (Pediatric and Adolescents, Adults), By Distribution Channel (Retail Pharmacies, E-Commerce), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Attention Deficit Hyperactivity Disorder (ADHD) Market Overview

The Global Attention Deficit Hyperactivity Disorder (ADHD) Market reached USD 15.7 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 21.9 billion by 2030. The Global Attention Deficit Hyperactivity Disorder Market is expected to exhibit a CAGR 4.3% during the forecast period 2023-2030. The Global Attention Deficit Hyperactivity Disorder Market has grown significantly in recent years and is projected to continue its upward trend.

The market is going through a period of significant change fueled by several directions, such as the shift towards non-stimulant medications, the expansion of digital health solutions, and the growing focus on combination therapies.

Furthermore, the increasing prevalence of ADHD, growing public awareness, and growing emphasis on R&Ds are driving up the size of the attention deficit hyperactivity disorder market. Due to continuous research and developments by introduction of novel drug, formulation, and treatment, the market is seeing an increase in demand from North American regions. With significant competitors like Supernus Pharmaceuticals, Inc., Pfizer Inc, Novartis AG, and others actively operating in the market the market is expected to grow in the forecast period.

Attention Deficit Hyperactivity Disorder (ADHD) Market Scope

For More Insights about the Market Request Free Sample

Attention Deficit Hyperactivity Disorder (ADHD) Market Dynamics

The Increasing Prevalence of ADHD to Drive the Growth of the Attention Deficit Hyperactivity Disorder Market

The global prevalence of ADHD has been gradually growing. Changes in lifestyle, genetic predisposition, environmental variables, and increased detection and diagnosis have all contributed to the increase. This growing patient pool has been a major driver of the ADHD market's expansion. As a result, the market for ADHD drugs, therapies, and interventions to manage symptoms and enhance functioning has increased. This demand has been the subject of research and development activities.

The increase in new ADHD diagnoses among females in older age groups is especially significant. Between 2020 and 2022, the prevalence of ADHD diagnosis among females aged 23-29 and 30-49 nearly doubled, adding to the overall increase in ADHD cases. The increased prevalence of ADHD is a major factor driving market growth.

Advancements in Treatment will Drive the Demand for Attention Deficit Hyperactivity Disorder Market.

Research and development efforts in the ADHD field have introduced new medicines, formulations, and treatment strategies. Pharmaceutical businesses and research organizations are actively investing in developing novel drugs, extended-release formulations, and alternative routes of administration.

BioLite, Inc., in collaboration with ABVC BioPharma, Inc, is conducting a phase II clinical trial to evaluate the tolerability and efficacy of PDC-1421 Capsule treatment in adult patients with attention-deficit hyperactivity disorder (ADHD). The trial’s primary objective is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary aim is to evaluate the safety of PDC-1421 capsules in subjects receiving PDC-1421 at various dose levels. Thus driving the market growth over the forecast period.

The Adverse Events Associated with these Drugs will Hamper the Growth of the Market.

Medications used in the global ADHD market, such as methylphenidate (e.g., Ritalin, Concerta), amphetamine-based drugs (e.g., Adderall, Vyvanse), and atomoxetine (e.g., Strattera), may have adverse effects. However, their occurrence and severity vary between individuals. Common adverse effects include loss of appetite, insomnia, gastrointestinal difficulties, headaches, elevated heart rate and blood pressure, mood changes, tics, and probable growth inhibition in youngsters. 

Individuals should discuss potential adverse effects with their healthcare professionals and be thoroughly monitored during therapy. The benefits of medication in managing ADHD symptoms frequently outweigh the potential side effects, although individual reactions to treatment can vary. Thus owing the above factors, the market is expected to restrain over the forecast period.

Attention Deficit Hyperactivity Disorder (ADHD) Market Segment Analysis

The Global Attention Deficit Hyperactivity Disorder Market is segmented based on drug type, age group, distribution channel, and region.

Owing to the Effectiveness, the Stimulant Segment Accounted for Approximately 54.4% of the Attention Deficit Hyperactivity Disorder Market Share.

Stimulant medications segment such as methylphenidate and amphetamines, will see a significant increase in the market due to their widespread use and demonstrated effectiveness in addressing ADHD symptoms such as short attention span, impulsive behavior, and hyperactivity. These medications have been shown to reduce disruptive behaviors, fidgeting, and other hyperactive symptoms in around 70% of adults and 70-80% of children with ADHD. 

Children, adolescents, and adults with ADHD are routinely administered amphetamines (e.g., Adderall), methylphenidate (e.g., Ritalin and Concerta), and dextroamphetamine, for instance, in June 2023. Xelstrym (dextroamphetamine), a new stimulant medicine, is now available to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 to 17 and people aged 18 and older. The Food and Drug Administration (FDA) has approved Xelstrym as the only transdermal amphetamine patch. Thus owing to the above factors, the segment will dominate over the forecast period.

Source: DataM Intelligence Analysis (2023)

Global Attention Deficit Hyperactivity Disorder (ADHD) Market Geographical Penetration

North America Accounted for Approximately 62.4% of the Market Share in 2022, Owing to the Technological Advancements and Better Government Initiatives

The global market for ADHD is dominated by North America, in notably the United States. High diagnostic rates, growing prevalence, a developed healthcare infrastructure and rising healthcare costs are among the primary factors. Due to the region's focus on raising awareness of ADHD, accessibility to specialized treatment facilities, and significant investment in research and development, it has a strong market presence.

For instance, a 2022 article published by the National Library of Medicine titled "ADHD Diagnostic Trends: Increased Recognition or Overdiagnosis" shows that the prevalence of ADHD in the US is substantially higher, impacting about 8.7% or 5.3 million children. 

In addition, a study titled "Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States" that was published in the Journal of Medical Economics shows that the annual excess societal costs associated with ADHD are significant, estimated to be $19.4 billion for children ($6,799 per child) and $13.8 billion for adolescents ($8,349 per adolescent). Hence, the market is expected to drive over the forecast period due to the above factors.

Source: DataM Intelligence Analysis (2023)

Attention Deficit Hyperactivity Disorder (ADHD) Market Companies

The major global players in the attention deficit hyperactivity disorder market include Supernus Pharmaceuticals, Inc., Pfizer Inc, Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, Hisamitsu Pharmaceutical Co., Inc., Chongqing Fujin Biology Medical Company, Purdue Pharma LP, and among others. 

COVID-19 Impact on Attention Deficit Hyperactivity Disorder (ADHD) Market 

Russia Ukraine Conflict Analysis

The conflict between Russia and Ukraine has the potential to have an array of effects on the global market for ADHD. There are several important things to take into account, including disruptions in the supply chains for ADHD medications, the state of the economy, problems with the healthcare system, and the psychological effects on people. 

These elements result in possible shortages, varying demands, restricted access to healthcare services, and a rise in the prevalence of ADHD. It will be essential to keep an eye on the situation and take the necessary steps to prevent disruptions and guarantee that ADHD medicines remain available and easily accessible.

By Drug Type

• Stimulant
• Non-stimulant 

By Age Group

• Pediatric and Adolescents
• Adults

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On June 8, 2022, Akili, a digital medicine firm, has launched EndeavorOTC, a new immersive mobile video game treatment intended to improve attention in adults suffering from attention deficit hyperactivity disorder (ADHD).
• On December 2, 2022, Tris Pharma, Inc announced that their agreement has been expanded, granting Pediatrix Therapeutics the right to commercialize its full FDA-approved ADHD portfolio as well as ADHD pipeline products in China.
• On May 25, 2022, The FDA expanded its approval of a non-stimulant medicine, viloxazine extended-release capsules, commonly known as Qelbree, for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

Why Purchase the Report?

• To visualize the Global Attention Deficit Hyperactivity Disorder Market segmentation based on drug type, age group, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of attention deficit hyperactivity disorder market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Attention Deficit Hyperactivity Disorder Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies